CD80 antibody

Catalog No. ABIN7457845

The Armenian Hamster Monoclonal anti-CD80 antibody has been validated for FACS and BR. It is suitable to detect CD80 in samples from Mouse.

Quick Overview for CD80 antibody (ABIN7457845)

Target: CD80

Reactivity: Mouse

Host: Armenian Hamster

Clonality: Monoclonal

Conjugate: This CD80 antibody is un-conjugated

Application: Flow Cytometry (FACS), Blocking Reagent (BR)

Clone: 16-10A1

Product Details anti-CD80 Antibody

Purification: Purified

Sterility: 0.2 μm filtered

Endotoxin Level: Low Endotoxin: Endotoxin level is < 2 EU/mg as Determined by LAL gel clotting assay.

Isotype: IgG

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Matching Isotype Control: AF/LE Purified Armenian Hamster IgG Isotype Control (ABIN7469872)

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: PBS, pH 7.2. Azide Free (AF)/Low Endotoxin (LE)

Preservative: Azide free

Storage: 4 °C

Storage Comment: Store at 2~8°C. Do not freeze.

Target Details for CD80

Target: CD80

Alternative Name: CD80

Background: T-lymphocyte activation antigen CD80,Cd80,Activation B7-1 antigen,B7,CD80 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD80 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD80 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD80 appears to be expressed later in the immune response than CD86. CD80 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Gene ID: 12519

UniProt: Q00609

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints